Top

Published in:

Open Access 01-01-2019 | Review Article

Heart toxicity from breast cancer radiotherapy

Current findings, assessment, and prevention

Authors: Prof. Dr. Marc D. Piroth, René Baumann, Wilfried Budach, Jürgen Dunst, Petra Feyer, Rainer Fietkau, Wulf Haase, Wolfgang Harms, Thomas Hehr, David Krug, Arnd Röser, Felix Sedlmayer, Rainer Souchon, Frederik Wenz, Rolf Sauer

Published in: Strahlentherapie und Onkologie | Issue 1/2019

Abstract

Background

Late cardiac toxicities caused by (particularly left-sided) breast radiotherapy (RT) are now recognized as rare but relevant sequelae, which has prompted research on risk structure identification and definition of threshold doses to heart subvolumes. The aim of the present review was to critically discuss the clinical evidence on late cardiac reactions based on dose-dependent outcome reports for mean heart doses as well as doses to cardiac substructures.

Methods

A literature review was performed to examine clinical evidence on radiation-induced heart toxicities. Mean heart doses and doses to cardiac substructures were focused upon based on dose-dependent outcome reports. Furthermore, an overview of radiation techniques for heart protection is given and non-radiotherapeutic aspects of cardiotoxicity in the multimodal setting of breast cancer treatment are discussed.

Results

Based on available findings, the DEGRO breast cancer expert panel recommends the following constraints: mean heart dose <2.5 Gy; D_meanLV (mean dose left ventricle) < 3 Gy; V5_LV (volume of LV receiving ≥5 Gy) < 17%; V23_LV (volume of LV receiving ≥23 Gy) < 5%; D_meanLAD (mean dose left descending artery) < 10 Gy; V30_LAD (volume of LAD receiving ≥30 Gy) < 2%; V40_LAD (volume of LAD receiving ≥40 Gy) < 1%.

Conclusion

In addition to mean heart dose, breast cancer RT treatment planning should also include constraints for cardiac subvolumes such as LV and LAD. The given constraints serve as a clinicians’ aid for ensuring adequate heart protection. The individual decision between sufficient protection of cardiac structures versus optimal target volume coverage remains in the physician’s hand. The risk of breast cancer-specific mortality and a patient’s cardiac risk factors must be individually weighed up against the risk of radiation-induced cardiotoxicity.

Clark RM, Whelan T, Levine M et al (1996) Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst 88(22):1659–1664CrossRefPubMed

Fisher B, Anderson S, Redmond CK et al (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333(22):1456–1461. https://doi.org/10.1056/NEJM199511303332203CrossRefPubMed

Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106. https://doi.org/10.1016/S0140-6736(05)67887-7CrossRefPubMed

Cuzick J, Stewart H, Rutqvist L et al (1994) Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12(3):447–453CrossRefPubMed

Darby S, McGale P, Peto R et al (2003) Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ 326(7383):256–257CrossRefPubMedPubMedCentral

Roychoudhuri R, Robinson D, Putcha V et al (2007) Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer 7:9. https://doi.org/10.1186/1471-2407-7-9CrossRefPubMedPubMedCentral

Darby SC, McGale P, Taylor CW et al (2005) Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6(8):557–565. https://doi.org/10.1016/S1470-2045(05)70251-5CrossRefPubMed

Bouillon K, Haddy N, Delaloge S et al (2011) Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol 57(4):445–452. https://doi.org/10.1016/j.jacc.2010.08.638CrossRefPubMed

Harris EE, Correa C, Hwang WT et al (2006) Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 24(25):4100–4106. https://doi.org/10.1200/JCO.2005.05.1037CrossRefPubMed

10.

Taylor CW, Nisbet A, McGale P et al (2007) Cardiac exposures in breast cancer radiotherapy: 1950s–1990s. Int J Radiat Oncol Biol Phys 69(5):1484–1495. https://doi.org/10.1016/j.ijrobp.2007.05.034CrossRefPubMed

11.

Taylor CW, Nisbet A, McGale P et al (2009) Cardiac doses from Swedish breast cancer radiotherapy since the 1950s. Radiother Oncol 90(1):127–135. https://doi.org/10.1016/j.radonc.2008.09.029CrossRefPubMed

12.

Taylor CW, Povall JM, McGale P et al (2008) Cardiac dose from tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys 72(2):501–507. https://doi.org/10.1016/j.ijrobp.2007.12.058CrossRefPubMed

13.

Weberpals J, Jansen L, Muller OJ et al (2018) Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J. https://doi.org/10.1093/eurheartj/ehy167CrossRefPubMed

14.

Andratschke N, Maurer J, Molls M et al (2011) Late radiation-induced heart disease after radiotherapy. Clinical importance, radiobiological mechanisms and strategies of prevention. Radiother Oncol 100(2):160–166. https://doi.org/10.1016/j.radonc.2010.08.010CrossRefPubMed

15.

Becker-Schiebe M, Stockhammer M, Hoffmann W et al (2016) Does mean heart dose sufficiently reflect coronary artery exposure in left-sided breast cancer radiotherapy? : influence of respiratory gating. Strahlenther Onkol 192(9):624–631. https://doi.org/10.1007/s00066-016-1011-yCrossRefPubMed

16.

Duma MN, Munch S, Oechsner M et al (2017) Are heart toxicities in breast cancer patients important for radiation oncologists? A practice pattern survey in German speaking countries. BMC Cancer 17(1):563. https://doi.org/10.1186/s12885-017-3548-2CrossRefPubMedPubMedCentral

17.

Mehta LS, Watson KE, Barac A, Beckie TM (2018) Cadiovascular disease and breast cancer: where these entities intersect. Circulation 137(8):e30. https://doi.org/10.1161/CIR.0000000000000556CrossRefPubMedPubMedCentral

18.

Tapio S (2016) Pathology and biology of radiation-induced cardiac disease. J Radiat Res 57(5):439–448. https://doi.org/10.1093/jrr/rrw064CrossRefPubMedPubMedCentral

19.

Adams MJ, Hardenbergh PH, Constine LS et al (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45(1):55–75CrossRefPubMed

20.

Stewart FA, Seemann I, Hoving S et al (2013) Understanding radiation-induced cardiovascular damage and strategies for intervention. Clin Oncol (R Coll Radiol) 25(10):617–624. https://doi.org/10.1016/j.clon.2013.06.012CrossRef

21.

Lusis AJ (2000) Atherosclerosis. Nature 407(6801):233–241. https://doi.org/10.1038/35025203CrossRefPubMedPubMedCentral

22.

Nilsson G, Holmberg L, Garmo H et al (2012) Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 30(4):380–386. https://doi.org/10.1200/JCO.2011.34.5900CrossRefPubMed

23.

Moignier A, Broggio D, Derreumaux S et al (2015) Coronary stenosis risk analysis following Hodgkin lymphoma radiotherapy: A study based on patient specific artery segments dose calculation. Radiother Oncol 117(3):467–472. https://doi.org/10.1016/j.radonc.2015.07.043CrossRefPubMed

24.

Marks LB, Yu X, Prosnitz RG et al (2005) The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63(1):214–223. https://doi.org/10.1016/j.ijrobp.2005.01.029CrossRefPubMed

25.

Erven K, Jurcut R, Weltens C et al (2011) Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients. Int J Radiat Oncol Biol Phys 79(5):1444–1451. https://doi.org/10.1016/j.ijrobp.2010.01.004CrossRefPubMed

26.

Heggemann F, Grotz H, Welzel G et al (2015) Cardiac function after multimodal breast cancer therapy assessed with functional magnetic resonance imaging and echocardiography imaging. Int J Radiat Oncol Biol Phys 93(4):836–844. https://doi.org/10.1016/j.ijrobp.2015.07.2287CrossRefPubMed

27.

D’Errico MP, Grimaldi L, Petruzzelli MF et al (2012) N‑terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys 82(2):e239–e246. https://doi.org/10.1016/j.ijrobp.2011.03.058CrossRefPubMed

28.

Skytta T, Tuohinen S, Boman E et al (2015) Troponin T‑release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. Radiat Oncol 10:141. https://doi.org/10.1186/s13014-015-0436-2CrossRefPubMedPubMedCentral

29.

Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368(11):987–998. https://doi.org/10.1056/NEJMoa1209825CrossRefPubMed

30.

van den Bogaard VA, Ta BD, van der Schaaf A et al (2017) Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol 35(11):1171–1178. https://doi.org/10.1200/JCO.2016.69.8480CrossRefPubMedPubMedCentral

31.

Hahn E, Jiang H, Ng A et al (2017) Late cardiac toxicity after mediastinal radiation therapy for Hodgkin Lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol Phys 98(5):1116–1123. https://doi.org/10.1016/j.ijrobp.2017.03.026CrossRefPubMed

32.

Carr ZA, Land CE, Kleinerman RA et al (2005) Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys 61(3):842–850. https://doi.org/10.1016/j.ijrobp.2004.07.708CrossRefPubMed

33.

Pirie K, Peto R, Reeves GK et al (2013) The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 381(9861):133–141. https://doi.org/10.1016/S0140-6736(12)61720-6CrossRefPubMedPubMedCentral

34.

Taylor C, Correa C, Duane FK et al (2017) Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 35(15):1641–1649. https://doi.org/10.1200/JCO.2016.72.0722CrossRefPubMedPubMedCentral

35.

Jain D, Russell RR, Schwartz RG et al (2017) Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions. Curr Cardiol Rep 19(5):36. https://doi.org/10.1007/s11886-017-0846-xCrossRefPubMed

36.

Dong J, Chen H (2018) Cardiotoxicity of anticancer therapeutics. Front Cardiovasc Med 5:9. https://doi.org/10.3389/fcvm.2018.00009CrossRefPubMedPubMedCentral

37.

Rygiel K (2017) Cardiotoxic effects of radiotherapy and strategies to reduce them in patients with breast cancer: an overview. J Cancer Res Ther 13(2):186–192. https://doi.org/10.4103/0973-1482.187303CrossRefPubMed

38.

Duma MN, Molls M, Trott KR (2014) From heart to heart for breast cancer patients—cardiovascular toxicities in breast cancer radiotherapy. Strahlenther Onkol 190(1):5–7. https://doi.org/10.1007/s00066-013-0465-4CrossRefPubMed

39.

Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801. https://doi.org/10.1093/eurheartj/ehw211CrossRefPubMed

40.

Hooning MJ, Botma A, Aleman BM et al (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99(5):365–375. https://doi.org/10.1093/jnci/djk064CrossRefPubMed

41.

Munshi A, Khataniar N, Sarkar B et al (2018) Spatial orientation of coronary arteries and its implication for breast and thoracic radiotherapy-proposing “coronary strip” as a new organ at risk. Strahlenther Onkol. https://doi.org/10.1007/s00066-018-1299-xCrossRefPubMed

42.

Piroth MD, Petz D, Pinkawa M et al (2016) Usefulness of a thermoplastic breast bra for breast cancer radiotherapy : a prospective analysis. Strahlenther Onkol 192(9):609–616. https://doi.org/10.1007/s00066-016-0981-0CrossRefPubMed

43.

Tan W, Liu D, Xue C et al (2012) Anterior myocardial territory may replace the heart as organ at risk in intensity-modulated radiotherapy for left-sided breast cancer. Int J Radiat Oncol Biol Phys 82(5):1689–1697. https://doi.org/10.1016/j.ijrobp.2011.03.009CrossRefPubMed

44.

Tan W, Wang X, Qiu D et al (2011) Dosimetric comparison of intensity-modulated radiotherapy plans, with or without anterior myocardial territory and left ventricle as organs at risk, in early-stage left-sided breast cancer patients. Int J Radiat Oncol Biol Phys 81(5):1544–1551. https://doi.org/10.1016/j.ijrobp.2010.09.028CrossRefPubMed

45.

Wenz F, Budach W (2017) Personalized radiotherapy for invasive breast cancer in 2017 : National S3 guidelines and DEGRO and AGO recommendations. Strahlenther Onkol 193(8):601–603. https://doi.org/10.1007/s00066-017-1158-1CrossRefPubMed

46.

Lauk S, Ruth S, Trott KR (1987) The effects of dose-fractionation on radiation-induced heart disease in rats. Radiother Oncol 8(4):363–367CrossRefPubMed

47.

Appelt AL, Vogelius IR, Bentzen SM (2013) Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. Clin Oncol (r Coll Radiol) 25(3):147–152. https://doi.org/10.1016/j.clon.2012.07.012CrossRef

48.

Haviland JS, Owen JR, Dewar JA et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094. https://doi.org/10.1016/S1470-2045(13)70386-3CrossRefPubMed

49.

Whelan TJ, Pignol JP, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520. https://doi.org/10.1056/NEJMoa0906260CrossRefPubMed

50.

James M, Swadi S, Yi M et al (2018) Ischaemic heart disease following conventional and hypofractionated radiation treatment in a contemporary breast cancer series. J Med Imaging Radiat Oncol 62(3):425–431. https://doi.org/10.1111/1754-9485.12712CrossRefPubMed

51.

Pignol JP, Olivotto I, Rakovitch E et al (2008) A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26(13):2085–2092. https://doi.org/10.1200/JCO.2007.15.2488CrossRefPubMed

52.

Lohr F, El-Haddad M, Dobler B et al (2009) Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. Int J Radiat Oncol Biol Phys 74(1):73–80. https://doi.org/10.1016/j.ijrobp.2008.07.018CrossRefPubMed

53.

Boda-Heggemann J, Knopf AC, Simeonova-Chergou A et al (2016) Deep inspiration breath hold-based radiation therapy: a clinical review. Int J Radiat Oncol Biol Phys 94(3):478–492. https://doi.org/10.1016/j.ijrobp.2015.11.049CrossRefPubMed

54.

Schonecker S, Heinz C, Sohn M et al (2016) Reduction of cardiac and coronary artery doses in irradiation of left-sided breast cancer during inspiration breath hold : a planning study. Strahlenther Onkol 192(11):750–758. https://doi.org/10.1007/s00066-016-1039-zCrossRefPubMed

55.

Corradini S, Ballhausen H, Weingandt H et al (2018) Left-sided breast cancer and risks of secondary lung cancer and ischemic heart disease : effects of modern radiotherapy techniques. Strahlenther Onkol 194(3):196–205. https://doi.org/10.1007/s00066-017-1213-yCrossRefPubMed

56.

Sakka M, Kunzelmann L, Metzger M et al (2017) Cardiac dose-sparing effects of deep-inspiration breath-hold in left breast irradiation : Is IMRT more beneficial than VMAT? Strahlenther Onkol 193(10):800–811. https://doi.org/10.1007/s00066-017-1167-0CrossRefPubMed

57.

Coles CE, Griffin CL, Kirby AM et al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5‑year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390(10099):1048–1060. https://doi.org/10.1016/S0140-6736(17)31145-5CrossRefPubMedPubMedCentral

58.

Vaidya JS, Wenz F, Bulsara M et al (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5‑year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917):603–613. https://doi.org/10.1016/S0140-6736(13)61950-9CrossRefPubMed

59.

Strnad V, Ott OJ, Hildebrandt G et al (2016) 5‑year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387 (10015):229–238. https://doi.org/10.1016/S0140-6736(15)00471-7CrossRef

Title: Heart toxicity from breast cancer radiotherapy
Current findings, assessment, and prevention
Authors: Prof. Dr. Marc D. Piroth
René Baumann
Wilfried Budach
Jürgen Dunst
Petra Feyer
Rainer Fietkau
Wulf Haase
Wolfgang Harms
Thomas Hehr
David Krug
Arnd Röser
Felix Sedlmayer
Rainer Souchon
Frederik Wenz
Rolf Sauer
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 1/2019
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1378-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Heart toxicity from breast cancer radiotherapy

Current findings, assessment, and prevention

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Dose variability in different lymph node levels during locoregional breast cancer irradiation: the impact of deep-inspiration breath hold

Feasibility of radiotherapy in nonagenarian patients: a retrospective study

Assessment of a guideline-based heart substructures delineation in left-sided breast cancer patients undergoing adjuvant radiotherapy

Additive Chemotherapie mit Cisplatin und Gemcitabin nach kurativ intendierter Radiochemotherapie verbessert das rezidivfreie Überleben von Nasopharynxkarzinompatienten mit noch nachzuweisender EBV-DNA-Last nicht

Kombinierte Immuntherapie für Patienten mit Hirnmetastasen eines malignen Melanoms: Deeskalation nur unter kontrollierten Bedingungen und engmaschiger Bildgebung

Long-term endothelial dysfunction in irradiated vessels: an immunohistochemical analysis